Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

7.08 9.44 12.78 15.02
P/S ratio
1.26 1.30 1.43 1.79
P/FCF ratio
8.80 10.18 7.92 14.46
P/Operating CF
27.59 20.64 21.08 254.39
P/B ratio
2.32 2.28 2.53 2.98
EV/Sales
1.02 1.01 1.07 1.48
EV/EBITDA
4.82 4.80 6.05 8.34
EV/FCF
7.09 7.91 5.93 11.95
Current Ratio
1.74 2.00 2.38 2.91
Net Debt/EBITDA
(5.10) (3.90) 74.24 (9.30)
Debt/Equity
0.29 0.17 0.09 0.00
Earnings Yield
14.12% 10.59% 7.82% 6.66%
Free Cash Flow Yield
11.36% 9.82% 12.63% 6.92%
Free Cash Flow per Share
0.19 0.29 0.30 0.03
Book value per Share
2.29 2.61 2.53 2.72
Free Cash Flow
9.66 14.46 15.42 1.62
EV/EBIT
6.42 6.20 8.26 11.22
Other line items

Show all line items

Columns are period end dates